None listed
Conditions
Interventions
Intervention1: Investigational Study Vaccine (BRV-TV): 2.0 mL administered orally at one of three dosage levels.
Control Intervention1: RotaTeq: 2.0 ml dose administered orally
Control Intervention2:
Sponsors
Shantha Biotechnics Limited
Eligibility
Inclusion criteria
Inclusion criteria: Healthy Adults: •Healthy Indian adult volunteers between 18 to 55 years of age. •No apparent signs or symptoms of ill health. •Properly informed about the study and having signed the informed consent form (ICF). In case of the volunteer being unable to read or write, having had the ICF explained to them in the presence of a study independent witness and the witness having signed the ICF; •Subject available for the entire period of the study and reachable by study staff for post vaccination follow-up. Healthy Infants: •Healthy infants, of either sex, 6-8 weeks of age at time of enrollment; •Born after a gestational period of 36-42 weeks with birth weight >=2kg; •Father, mother or other legally acceptable representative (guardian) properly informed about the study and having signed the informed consent form (ICF). In case of father, mother or other legally acceptable representative (guardian) being unable to read or write, having had the ICF explained to them in the presence of a study independent witness and the witness having signed the ICF; •Infant/Parent or guardian available for the entire period of the study and reachable by study staff for post-vaccination follow-up.
Exclusion criteria
Exclusion criteria: Healthy adults: •Known or suspected impairment of immunological function; •Known hypersensitivity to any component of the rotavirus vaccine; •Fever, with axillary temperature >=38.1oC (>=100.5oF); measured by study staff. •History of chronic diarrhea; •Clinical evidence of active gastrointestinal illness; •Receipt of any IM, oral, or IV corticosteroid treatment in the past 30 days •Subjects suspected to be HIV, HBV or HCV positive from the available clinical history •Any subject who cannot be adequately followed for safety; •Any conditions which, in the opinion of the investigator, might interfere with the evaluation of the study objectives. •Subject unable to maintain diary card •Participation in another clinical trial investigating a vaccine, drug, medical device or medicinal procedure in the 4 weeks preceding the trial vaccination. •Planned participation in another clinical trial during the present trial period. •Volunteers identified as employees of the investigator or study center, with direct involvement in the proposed study or studies under the direction of that investigator or study center as well as children, adopted or natural, of the employees or Investigator. Healthy Infants: •History of congenital abdominal disorders, intussusception, or abdominal surgery; •Infants exhibiting signs of severe malnutrition Known or suspected impairment of immunological function in subject or immediate family; •Developmental delay or Neurological disorder •Known hypersensitivity to any component of the rotavirus vaccine; •Prior receipt of any rotavirus vaccine; •Prior receipt of any dose of Diphtheria, Tetanus, Pertussis, Hepatitis B, Hib or polio virus containing vaccine(s). Birth dose of Hepatitis B and Oral Polio Vaccine is allowed to be administered to the infants as per the local immunization practices. Oral Polio Vaccines administered as a part of the National Pulse Polio Program are allowed to be administered to the infants. •Fever, with axillary temperature >=38.1oC (>=100.5oF); measured by study staff. •History of known rotavirus disease, chronic diarrhea, or failure to thrive; •Baseline level of ALT or AST 2.5 times the upper limit of normal; •Clinical evidence of active gastrointestinal illness including ongoing diarrheal episode (infants with GERD can participate in the study so long as this condition is well controlled with or without medication); •Receipt of any IM, oral, or IV corticosteroid treatment in the past 30 days (infants on inhaled steroids may be permitted to participate in the study); •Infants residing in a household with an immuno-compromised person (e.g., individuals with a congenital immunodeficiency, HIV infection, leukemia, lymphoma, Hodgkinâ??s disease, multiple myeloma, generalized malignancy, chronic renal failure, nephritic syndrome, organ or bone marrow transplantation, or those receiving immunosuppressive chemotherapy including long-term systemic corticosteroids); •Infants already laboratory confirmed or suspected to be HIV, HBV or HCV positive from the available clinical history or born to mothers known to be HIV, HBV or HCV positive.(no specific screening for the purpose of the study would be carried out) •Prior receipt of a blood transfus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cohort 1 (Healthy Adults) Frequency, severity, and causality of REs and other AEs following the dose of Investigational Rotavirus Vaccine as compared to REs and AEs reported for adults administered a single dose of Placebo. Cohort 2 (Healthy Infants) Sero-response rate at each antigen concentration level of Investigational Rotavirus vaccine/ Rotateq/Placebo Timepoint: Cohort 1 (Healthy Adults) 1O days post vaccination Cohort 2 (Healthy Infants) 28 days post 3rd dose of vaccination | — |
Secondary
| Measure | Time frame |
|---|---|
| Cohort 2 (Healthy Infants) â?¢Frequency, severity, and causality of REs and other AEs following the dose of Investigational Rotavirus Vaccine /Rotateq/Placebo Timepoint: Till 28 days post vaccination | — |
Countries
India
Contacts
Public ContactDr Mandeep Singh DhingraMD
Shantha Biotechnics Limited
Outcome results
None listed